Stockreport
IMDELLTRA's FDA Approval and Guideline Upgrade Could Be a Game Changer for Amgen (AMGN) [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Amgen recently announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) for adults with extensive stage small cell lung cancer (ES-SCLC) who have progressed after platinum-based chemotherapy, and the National Comprehensive Cancer Network updated its guidelines to list Tarlatamab as the only Category 1 preferred treatment option for this patient group.
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha][Seeking Alpha]
- Amgen (NASDAQ:AMGN) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.[MarketBeat]
- Accord Healthcare Announces Launch of Denosumab? - Second Biosimilar in Bone Health [Globe and Mail, The (Toronto, Canada)][Globe and Mail, The]
- Accord Healthcare Announces Launch of Denosumab? - Second Biosimilar in Bone Health [Yahoo! Finance][Yahoo! Finance]
- Is Amgen's Recent Rally Justified After Strong Clinical Trial Results? [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website
- More